The latest report by IMARC Group, titled “Neuromodulation Market Report by Technology (Internal Neuromodulation, External Neuromodulation), Biomaterial (Metallic Biomaterials, Polymeric Biomaterials, Ceramic Biomaterials), Application (Parkinson's Disease, Epilepsy, Depression, Dystonia, Pain Management, and Others), and Region 2025-2033”, offers a comprehensive analysis of the industry, which comprises insights on the neuromodulation market share.

Neuromodulation Market Outlook 2025-2033

The global neuromodulation market size reached USD 8.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 18.8 Billion by 2032, exhibiting a growth rate (CAGR) of 9.2% during 2024-2032.

Factors Affecting the Growth of the Neuromodulation Industry:

• Rising Prevalence of Neurological Disorders

The neuromodulation market is significantly driven by the increasing prevalence of neurological disorders such as Parkinson’s disease, epilepsy, chronic pain, and depression. As the global population ages, the incidence of these conditions is expected to rise, creating a higher demand for effective treatment options. Neuromodulation therapies, which involve direct modulation of nerve activity, offer promising results for managing symptoms and improving the quality of life for patients with these disorders. The growing awareness of the benefits of neuromodulation, coupled with the rising number of patients seeking alternative treatments, is propelling the market forward.

• Technological Advancements in Neuromodulation Devices

Technological advancements in neuromodulation devices are a major driver of market growth. Innovations such as rechargeable implants, closed-loop systems, and minimally invasive procedures have significantly enhanced the efficacy, safety, and patient compliance of neuromodulation therapies. These advancements make devices more user-friendly and accessible, broadening their application to a wider range of neurological conditions. Continuous research and development efforts are also leading to the discovery of new neuromodulation techniques and devices, further expanding the market. The improved precision and customization of treatment protocols made possible by these technologies are driving the adoption of neuromodulation therapies in clinical practice.

• Growing Demand for Non-Invasive Treatment Options

The increasing demand for non-invasive and minimally invasive treatment options is another key driver for the neuromodulation market. Patients and healthcare providers are increasingly favoring treatments that offer effective symptom management with fewer risks and shorter recovery times compared to traditional surgical methods. Non-invasive neuromodulation techniques, such as transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS), have gained popularity for their ability to treat conditions such as depression and chronic pain without the need for invasive procedures. The preference for these safer and more convenient treatment options is contributing to the rapid growth of the neuromodulation market.

For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/neuromodulation-market/requestsample

Competitive Landscape:

The competitive landscape of the market has been studied in the report with detailed profiles of the key players operating in the market.

Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., Nevro Corp., etc.

Neuromodulation Market Report Segmentation:

By Technology:

• Internal Neuromodulation
  • Spinal Cord Stimulation (SCS)
  • Deep Brain Stimulation (DBS)
  • Vagus Nerve Stimulation (VNS)
  • Sacral Nerve Stimulation (SNS)
  • Gastric Electrical Stimulation (GES)
• External Neuromodulation
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Transcranial Magnetic Stimulation (TMS)
  • Others

Internal neuromodulation represents the leading segment due to its direct and targeted stimulation of neural structures, offering effective treatment options for various neurological disorders with minimally invasive procedures.

By Biomaterial:

• Metallic Biomaterials
• Polymeric Biomaterials
• Ceramic Biomaterials

Metallic biomaterials account for the largest market share owing to their biocompatibility, durability, and reliability, making them suitable for long-term implantation in neuromodulation devices.

By Application:

• Parkinson's Disease
• Epilepsy
• Depression
• Dystonia
• Pain Management
• Others

Parkinson’s disease represents the largest segment as it is one of the most prevalent neurological disorders globally, driving demand for neuromodulation therapies to alleviate symptoms such as tremors, rigidity, and bradykinesia.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America's dominance in the neuromodulation market is attributed to factors such as advanced healthcare infrastructure, high prevalence of neurological disorders, supportive regulatory frameworks, and strong investments in research and development.

Global Neuromodulation Market Trends:

The global neuromodulation market is experiencing significant growth driven by the increasing prevalence of neurological disorders, such as chronic pain, Parkinson's disease, and epilepsy, driving demand for neuromodulation therapies as alternative treatment options. Apart from this, ongoing technological advancements in neuromodulation devices, including miniaturization, wireless connectivity, and closed-loop systems, enhance treatment efficacy, patient comfort, and convenience, fueling market growth. Additionally, the expanding applications of neuromodulation beyond traditional indications, such as psychiatric disorders, addiction, and obesity, present new opportunities for market growth. Furthermore, rising healthcare expenditure, improving healthcare infrastructure, and expanding reimbursement coverage for neuromodulation procedures are stimulating market expansion.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145